International Journal of Drug Delivery Technology · Jul 18, 2026

Clinical Evaluation of Shatapushpa Shatavari Modak in Perimenopausal Syndrome: An Open-Label Single-Arm Study

By Rajput D, Shirke P, Deore N

Background: Perimenopause is a transitional phase preceding menopause and is associated with somatic, psychological, and urogenital complaints.Hormone replacement therapy is available in modern medicine; however, the source document notes several concerns related to long-term use and adverse effects.Ayurveda describes this stage in relation to Vata predominance and Dhatukshaya, where Rasayana and supportive formulations may be clinically useful.[1,4] Objective: To evaluate the clinical effect of Shatapushpa Shatavari Modak in women with perimenopausal syndrome using the Menopausal Rating Scale (MRS). Methods:This was an open-label, single-arm clinical study conducted in the OPD of Streeroga and Prasutitantra.Women aged 35-55 years with clinical features of perimenopausal syndrome were included.Fifty-five patients were enrolled after baseline screening; three were withdrawn due to loss to follow-up and 52 completed the study.Each patient received one Modak of approximately 35 g orally once daily at Rasayana Kala for 60 days.Follow-up assessments were performed on day 30, day 60, and day 90.Outcomes were assessed using MRS subscale and total scores.Wilcoxon signed-rank test was applied because observations were recorded on an ordinal scale.Results: Significant improvement was observed in somatic, psychological, urogenital, and total MRS scores.Median somatic score reduced from 6 to 2.5 with 54.04% effect.Median psychological score reduced from 4 to 1 with 57.21% effect.Median urogenital score reduced from 5 to 3 with 37.31% effect.Total MRS median score reduced from 15.5 to 8 with 49.32% effect.Overall, 3.85% patients showed marked improvement, 40.38% showed moderate improvement, 53.85% showed mild improvement, and 1.92% showed no change.Conclusion: Shatapushpa Shatavari Modak showed statistically significant clinical improvement in perimenopausal syndrome, especially in somatic and psychological complaints.Further controlled trials with larger samples are recommended.

doi.org/10.25258/ijddt.16.66s.63Open accessInterventions

AgingResearch.News